Venmax Drugs & Pharmaceuticals Ltd Fair Value
VENMAXDRUGSPHARMACEUTICALSLTD · Healthcare · Current price
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹10 | -0% ROE fading to 12% over ~3 yrs, on ₹12 book |
| Relative P/E | ₹8 | EPS × 38.2 peer-median P/E |
| Graham floor | ₹8 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is Venmax Drugs & Pharmaceuticals Ltd undervalued?
We couldn't compute a reliable fair value for Venmax Drugs & Pharmaceuticals Ltd from the available data. This usually means key inputs (earnings, book value, or cash flow) are missing or inconsistent.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹10), Relative P/E (₹8), Graham floor (₹8). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹8 (bear) to ₹9 (base) to ₹10 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on Venmax Drugs & Pharmaceuticals Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.